John Mendelsohn, MD (Damon Runyon Grantee ’72–’74), president emeritus of MD Anderson Cancer Center, shared the 2018 Tang Prize in Biopharmaceutical Science with former Damon Runyon Sponsors Tony Hunter, PhD, at the Salk Institute and Brian J. Druker, MD, at the OHSU Knight Cancer Institute. Mendelsohn led the development of a novel targeted therapy: the anti-EGFR antibody cetuximab (Erbitux®). His efforts resulted in its approval by the FDA for the treatment of colon cancer and head/neck cancer. The trio is recognized for shaping the fields of precision medicine and targeted cancer drugs and will share the $1.33 million prize.

Read more about the study here.

This post was originally published by Damon Runyon Cancer Research Foundation. It is republished with permission.